Overview

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor (TNF )Inhibitor for the Treatment of Ankylosing Spondylitis

Status:
NOT_YET_RECRUITING

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to investigate the efficacy and safety of adalimumab in combination with secukinumab for the treatment of ankylosing spondylitis.

Phase:

PHASE4

Details

Lead Sponsor:

The Affiliated Hospital Of Guizhou Medical University

Treatments:

Adalimumab
secukinumab